Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/16/2005EP1514542A1 Medicinal compositions improving brain function and method for improving brain function
03/16/2005EP1514541A1 Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
03/16/2005EP1514540A1 Calcium-containing tissue strengthening agents and use thereof
03/16/2005EP1514539A2 Micro-encapsulated topical analgesic for pain relief and sleeve comprising it
03/16/2005EP1514536A1 Topical compositions
03/16/2005EP1514473A1 Low-salt or salt-free microbicidal composition based on isothiazolone derivatives and pyrion disulphide
03/16/2005EP1514116A1 Oxaliplatin anti-resistance agent
03/16/2005EP1514115A2 Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof
03/16/2005EP1513959A2 Antiviral inhibitions of capsid proteins
03/16/2005EP1513942A2 Galactosyl isomalt, method for production and use thereof
03/16/2005EP1513941A2 Preparation of microbial oil containing polyunsaturated fatty acids
03/16/2005EP1513922A1 Pasteurisation process for microbial cells and microbial oil
03/16/2005EP1513889A1 Hydrous gel and production process and use of the hydrous gel
03/16/2005EP1513880A1 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
03/16/2005EP1513870A2 Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same
03/16/2005EP1513864A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/16/2005EP1513862A2 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
03/16/2005EP1513861A2 New etonogestrel esters
03/16/2005EP1513859A2 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
03/16/2005EP1513858A2 Process for the preparation of heterocyclyl substituted adenosine derivatives
03/16/2005EP1513856A1 3-descladinosyl-6-o-carbamoyl and 6-o-carbonoyl macrolide antibacterial agents
03/16/2005EP1513853A2 Cardiolipin compositions, methods of preparation and use
03/16/2005EP1513848A2 Method of treating ischemia reperfusion injury using adenosine receptor antagonists
03/16/2005EP1513842A1 Substituted hexahydropyrrolo (1,2-a)pyrazines, octahydropyrido(1,2-a)pyrazines and decahydropyrazino(1,2-a)azepines
03/16/2005EP1513840A2 Compounds and compositions for the treatment of diabetes and diabetes-related disorders
03/16/2005EP1513839A1 3-substituted quinuclidines and their use
03/16/2005EP1513837A1 Thiazole derivatives as phosphodiesterase iv inhibitors
03/16/2005EP1513836A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
03/16/2005EP1513835A1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
03/16/2005EP1513834A1 Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same
03/16/2005EP1513833A1 Novel 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinoline-4-one derivatives, method for preparing same and pharmaceutical compositions containing same
03/16/2005EP1513832A2 Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
03/16/2005EP1513831A1 Novel compounds, their use and preparation
03/16/2005EP1513830A1 Bisindolyl-maleimid derivatives as kinase inhibitors
03/16/2005EP1513828A1 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
03/16/2005EP1513827A1 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
03/16/2005EP1513826A1 New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
03/16/2005EP1513825A2 Anti tubercular drug: compositions and methods
03/16/2005EP1513821A1 Protein kinase inhibitors
03/16/2005EP1513820A2 Compounds, compositions, and methods
03/16/2005EP1513818A2 Heterocyclic inhibitors of kinases
03/16/2005EP1513814A1 Novel piperidine compound
03/16/2005EP1513813A1 Opioid receptor antagonists
03/16/2005EP1513812A1 Substituted indoles
03/16/2005EP1513811A1 Non-peptidic brs-3 agonists
03/16/2005EP1513810A1 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
03/16/2005EP1513809A1 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
03/16/2005EP1513808A2 Fluorinated cyclic amides as dipeptidyl peptidase iv inhibitors
03/16/2005EP1513807A1 Pharmaceutical combination
03/16/2005EP1513806A1 New salts
03/16/2005EP1513804A1 Novel trans-lutein enriched xanthophyll ester concentrate and a process for its preparation
03/16/2005EP1513803A1 Ligands that are inhibitors of the rar receptors
03/16/2005EP1513800A1 N-benzoylureidocinnamate derivatives, method for production and use thereof
03/16/2005EP1513799A1 Amidoacetonitrile compounds and their use as pesticides
03/16/2005EP1513797A1 Agents and methods for the treatment of disorders associated with oxidative stress
03/16/2005EP1513796A2 Phenyloxyalkanoic acid derivatives as hppar activators
03/16/2005EP1513795A2 Propionic acid derivatives and their use as hppars activators
03/16/2005EP1513793A1 Novel ligands that are inhibitors of the rar receptors, process for preparing them and use thereof in human medicine and in cosmetics
03/16/2005EP1513589A1 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
03/16/2005EP1513588A2 Use of new etonogestrel esters
03/16/2005EP1513587A1 Self-administered contraceptive injection of oily solution
03/16/2005EP1513557A2 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
03/16/2005EP1513556A1 A process for the preparation of piroxicam: b-cyclodextrin inclusion compounds
03/16/2005EP1513555A1 Formulations of quinapril and related ace inhibitors
03/16/2005EP1513548A2 Method for reducing obstructive hydrocephalus
03/16/2005EP1513546A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
03/16/2005EP1513540A1 Pharmaceutical compositions comprising abacavir and lamivudine
03/16/2005EP1513539A1 Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases
03/16/2005EP1513537A1 Substituted porphyrins
03/16/2005EP1513536A1 Use of compounds that stimulate cgmp
03/16/2005EP1513535A2 Controlled release formulation of lamotrigine
03/16/2005EP1513534A2 Compounds for increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
03/16/2005EP1513533A2 Pharmaceutical active substance combination and the use thereof
03/16/2005EP1513532A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
03/16/2005EP1513531A1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
03/16/2005EP1513530A1 Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
03/16/2005EP1513529A1 Triple monoamine reuptake inhibitors for the treatment of chronic pain
03/16/2005EP1513528A1 Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride
03/16/2005EP1513526A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
03/16/2005EP1513525A1 Use of mglur5 antagonists for the treatment of gerd
03/16/2005EP1513524A2 Ether substituted imidazopyridines
03/16/2005EP1513523A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
03/16/2005EP1513522A2 Methods of treating conditions associated with an edg receptor
03/16/2005EP1513521A2 Pyranoindazoles and their use for the treatment of glaucoma
03/16/2005EP1513520A2 Substituted pyrrolines as kinase inhibitors
03/16/2005EP1513519A1 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
03/16/2005EP1513518A1 Use of nefopam for the treatment of nausea or emesis
03/16/2005EP1513517A1 Formulation of nefopam and its use in the treatment of pain
03/16/2005EP1513516A1 SUBSTITUTED 3-AMINO-THIENO(2,3-b) PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS ANDPROCESSES FOR PREPARING AND THEIR USES
03/16/2005EP1513515A2 Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
03/16/2005EP1513514A1 Lignan formulations
03/16/2005EP1513513A1 I CIS /i -2,6-DISUBSTITUTED PIPERIDINES FOR THE TREATMENT OF PSYCHOSTIMULANT ABUSE AND WITHDRAWAL, EATING DISORDERS, AND CENTRAL NERVOUS SYSTEM DISEASES AND PATHOLOGIES
03/16/2005EP1513512A2 Soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors.
03/16/2005EP1513511A1 (2s)-2-amino-4- [2-(ethanimidoylamino)ethyl]thio butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
03/16/2005EP1513510A1 The use of milnacipran for the treatment of tension-type headache
03/16/2005EP1513509A2 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
03/16/2005EP1513507A1 Transdermal analgesic systems with reduced abuse potential
03/16/2005EP1513505A1 An improved modified release preparation
03/16/2005EP1513504A1 Sustained release oral dosage forms of gabapentin
03/16/2005EP1513503A1 Extended release formulation of divalproex sodium
1 ... 4753 4754 4755 4756 4757 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 4771 4772 4773 ... 7860